Progressive axonal transport and synaptic protein changes correlate with behavioral and neuropathological abnormalities in the heterozygous Q175 KI mouse model of Huntington's disease

Human Molecular Genetics

Volumn 23, Issue 17, 2014, Pages 4510-4527

  Smith, Gaynor A ^a   Rocha, Emily M ^a   McLean, Jesse R ^a   Hayes, Melissa A ^a   Izen, Sarah C ^a   Isacson, Ole ^a   Hallett, Penelope J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; 5 HYDROXYINDOLEACETIC ACID; BETA TUBULIN; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; DOPAMINE; DYNACTIN; DYNEIN ADENOSINE TRIPHOSPHATASE; HUNTINGTIN; KIF3A PROTEIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; PHOSPHOPROTEIN DARPP 32; POSTSYNAPTIC DENSITY PROTEIN 95; RAB PROTEIN; SEROTONIN; SYNAPTOPHYSIN; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; TRANSLOCASE OF OUTER MITOCHONDRIAL MEMBRANE 20; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; SEROTONIN TRANSPORTER; SLC6A4 PROTEIN, MOUSE;

AMYGDALOID NUCLEUS; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL GANGLION; BRAIN ATROPHY; BRAIN CORTEX; BRAIN DEGENERATION; CAG REPEAT; COGNITIVE DEFECT; CONTROLLED STUDY; CORPUS STRIATUM; CORRELATION ANALYSIS; CORTICAL THICKNESS (BRAIN); DISEASE COURSE; GENOTYPE; HETEROZYGOSITY; HIPPOCAMPUS; HUNTINGTON CHOREA; HYPOTHALAMUS; LATENT PERIOD; LATERAL BRAIN VENTRICLE; MOTOR COORDINATION; MOTOR CORTEX; MOUSE; NERVE FIBER TRANSPORT; NESTING; NEUROPATHOLOGY; NONHUMAN; NUCLEUS ACCUMBENS; PHENOTYPE; POSTSYNAPTIC DENSITY; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; PYRIFORM CORTEX; SENSORY CORTEX; SUBSTANTIA NIGRA; THALAMUS; WORKING MEMORY; AGING; ANIMAL; ATROPHY; C57BL MOUSE; CELL INCLUSION; CYTOSKELETON; DISEASE MODEL; GENE TARGETING; GENETICS; HETEROZYGOTE; METABOLISM; METABOLOME; MUTATION; NEOSTRIATUM; PATHOLOGY; SYNAPSE;

AGING; ANIMALS; ATROPHY; AXONAL TRANSPORT; BEHAVIOR, ANIMAL; BRAIN-DERIVED NEUROTROPHIC FACTOR; CYTOSKELETON; DISEASE MODELS, ANIMAL; GENE KNOCK-IN TECHNIQUES; HETEROZYGOTE; HUNTINGTON DISEASE; INCLUSION BODIES; METABOLOME; MICE; MICE, INBRED C57BL; MUTATION; NEOSTRIATUM; NEUROTRANSMITTER AGENTS; RECEPTOR, TRKB; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SYNAPSES;

EID: 84905667224     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddu166     Document Type: Article

References (84)

1. Dragatsis, I., Levine, M.S. and Zeitlin, S. (2000) Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice. Nat. Genet., 26, 300-306.
2. Bayram-Weston, Z., Jones, L., Dunnett, S.B. and Brooks, S.P. (2012) Light and electron microscopic characterization of the evolution of cellular pathology in HdhQ92 Huntington's disease knock-in mice. Brain Res. Bull., 88, 171-181.
3. Bayram-Weston, Z., Torres, E.M., Jones, L., Dunnett, S.B. and Brooks, S.P. (2012) Light and electron microscopic characterization of the evolution of cellular pathology in the Hdh(CAG)150 Huntington's disease knock-in mouse. Brain Res. Bull., 88, 189-198.
4. Woodman, B., Butler, R., Landles, C., Lupton, M.K., Tse, J., Hockly, E., Moffitt, H., Sathasivam, K. and Bates, G.P. (2007) The Hdh(Q150/Q150) knock-in mouse model of HD and the R6/2 exon 1 model develop comparable and widespread molecular phenotypes. Brain Res. Bull., 72, 83-97.
5. Menalled, L., El-Khodor, B.F., Patry, M., Suarez-Farinas, M., Orenstein, S.J., Zahasky, B., Leahy, C., Wheeler, V., Yang, X.W., MacDonald, M. et al. (2009) Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models. Neurobiol. Dis., 35, 319-336.
6. Chung, C.Y., Koprich, J.B., Siddiqi, H. and Isacson, O. (2009) Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy. J. Neurosci., 29, 3365-3373.
7. Vonsattel, J.P., Myers, R.H., Stevens, T.J., Ferrante, R.J., Bird, E.D. and Richardson, E.P. Jr (1985) Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neurol., 44, 559-577.
8. Macdonald, V. and Halliday,G. (2002) Pyramidal cell loss in motor cortices in Huntington's disease. Neurobiol. Dis., 10, 378-386.
9. Rosas, H.D., Liu, A.K., Hersch, S., Glessner, M., Ferrante, R.J., Salat, D.H., van der Kouwe, A., Jenkins, B.G., Dale, A.M. and Fischl, B. (2002) Regional and progressive thinning of the cortical ribbon in Huntington's disease. Neurology, 58, 695-701.
10. Sapp, E., Penney, J., Young, A., Aronin, N., Vonsattel, J.P. and DiFiglia, M. (1999) Axonal transport of N-terminal huntingtin suggests early pathology of corticostriatal projections in Huntington disease. J. Neuropathol. Exp. Neurol., 58, 165-173.
11. Zheng, Z. and Diamond, M.I. (2012) Huntington disease and the huntingtin protein. Prog. Mol. Biol. Transl. Sci., 107, 189-214.
12. Crupi, D., Ghilardi, M.F., Mosiello, C., Di Rocco, A., Quartarone, A. and Battaglia, F. (2008) Cortical and brainstem LTP-like plasticity in Huntington's disease. Brain Res. Bull., 75, 107-114.
13. Cummings, D.M., Milnerwood, A.J., Dallerac, G.M., Vatsavayai, S.C., Hirst, M.C. and Murphy, K.P. (2007) Abnormal cortical synaptic plasticity in a mouse model of Huntington's disease. Brain Res. Bull., 72, 103-107.
14. Seo, H., Sonntag, K.C. and Isacson, O. (2004) Generalized brain and skin proteasome inhibition in Huntington's disease. Ann. Neurol., 56, 319-328.
15. Zuccato, C., Marullo, M., Vitali, B., Tarditi, A., Mariotti, C., Valenza, M., Lahiri, N., Wild, E.J., Sassone, J., Ciammola, A. et al. (2011) Brain-derived neurotrophic factor in patients with Huntington's disease. PLoS One, 6, e22966.
16. Millecamps, S. and Julien, J.P. (2013) Axonal transport deficits and neurodegenerative diseases. Nat. Rev. Neurosci., 14, 161-176.
17. Richards, P., Didszun, C., Campesan, S., Simpson, A., Horley, B., Young, K.W., Glynn, P., Cain, K., Kyriacou, C.P., Giorgini, F. et al. (2011) Dendritic spine loss and neurodegeneration is rescued by Rab11 in models of Huntington's disease. Cell Death Differ., 18, 191-200.
18. Hoffner, G., Kahlem, P. and Djian, P. (2002) Perinuclear localization of huntingtin as a consequence of its binding to microtubules through an interaction with beta-tubulin: relevance to Huntington's disease. J. Cell. Sci., 115, 941-948.
19. DiFiglia, M., Sapp, E., Chase, K., Schwarz, C., Meloni, A., Young, C., Martin, E., Vonsattel, J.P., Carraway, R., Reeves, S.A. et al. (1995) Huntingtin is a cytoplasmic protein associated with vesicles in humanand rat brain neurons. Neuron, 14, 1075-1081.
20. Velier, J., Kim, M., Schwarz, C., Kim, T.W., Sapp, E., Chase, K., Aronin, N. and DiFiglia, M. (1998) Wild-type and mutant huntingtins function in vesicle trafficking in the secretory and endocytic pathways. Exp. Neurol., 152, 34-40.
21. Waelter, S., Scherzinger, E., Hasenbank, R., Nordhoff, E., Lurz, R., Goehler, H., Gauss, C., Sathasivam, K., Bates, G.P., Lehrach, H. et al. (2001) The huntingtin interacting protein HIP1 is a clathrin and alpha-adaptin-binding protein involved in receptor-mediated endocytosis. Hum. Mol. Genet., 10, 1807-1817.
22. Szebenyi, G., Morfini, G.A., Babcock, A., Gould, M., Selkoe, K., Stenoien, D.L., Young, M., Faber, P.W., MacDonald, M.E., McPhaul, M.J. et al. (2003) Neuropathogenic forms of huntingtin and androgen receptor inhibit fast axonal transport. Neuron, 40, 41-52.
23. Gunawardena, S., Her, L.S., Brusch, R.G., Laymon, R.A., Niesman, I.R., Gordesky-Gold, B., Sintasath, L., Bonini, N.M. and Goldstein, L.S. (2003) Disruption of axonal transport by loss of huntingtin or expression of pathogenic polyQ proteins in Drosophila. Neuron, 40, 25-40.
24. Lee, W.C., Yoshihara, M. and Littleton, J.T. (2004) Cytoplasmic aggregates trap polyglutamine-containing proteins and block axonal transport in a Drosophila model of Huntington's disease. Proc. Natl. Acad. Sci. USA, 101, 3224-3229.
25. Trushina, E., Dyer, R.B., Badger, J.D. 2nd, Ure, D., Eide, L., Tran, D.D., Vrieze, B.T., Legendre-Guillemin, V., McPherson, P.S., Mandavilli, B.S. et al. (2004) Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro. Mol. Cell Biol., 24, 8195-8209.
26. Li, H., Li, S.H., Yu, Z.X., Shelbourne, P. and Li, X.J. (2001) Huntingtin aggregate-associated axonal degeneration is an early pathological event in Huntington's disease mice. J. Neurosci., 21, 8473-8481.
27. Dompierre, J.P., Godin, J.D., Charrin, B.C., Cordelieres, F.P., King, S.J., Humbert, S. and Saudou, F. (2007) Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington's disease by increasing tubulin acetylation. J. Neurosci., 27, 3571-3583.
28. Block-Galarza, J., Chase, K.O., Sapp, E., Vaughn, K.T., Vallee, R.B., DiFiglia, M. and Aronin, N. (1997) Fast transport and retrograde movement of huntingtin and HAP 1 in axons. Neuroreport, 8, 2247-2251.
29. Braunstein, K.E., Eschbach, J., Rona-Voros, K., Soylu, R., Mikrouli, E., Larmet, Y., Rene, F., Gonzalez De Aguilar, J.L., Loeffler, J.P., Muller, H.P. et al. (2010)Apoint mutation in the dynein heavy chain gene leads to striatal atrophy and compromises neurite outgrowth of striatal neurons. Hum. Mol. Genet., 19, 4385-4398.
30. Zuccato, C. and Cattaneo, E. (2007) Role of brain-derived neurotrophic factor in Huntington's disease. Prog. Neurobiol., 81, 294-330.
31. Zuccato, C., Ciammola, A., Rigamonti, D., Leavitt, B.R., Goffredo, D., Conti, L., MacDonald, M.E., Friedlander, R.M., Silani, V., Hayden, M.R. et al. (2001) Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science, 293, 493-498.
32. Liot, G., Zala, D., Pla, P., Mottet, G., Piel, M. and Saudou, F. (2013) Mutant Huntingtin alters retrograde transport of TrkB receptors in striatal dendrites. J. Neurosci., 33, 6298-6309.
33. HD-iPSC-Consortium (2012) Induced pluripotent stem cells from patients with Huntington's disease show CAG-repeat-expansion-associated phenotypes. Cell Stem Cell, 11, 264-278.
34. Li, X., Standley, C., Sapp, E., Valencia, A., Qin, Z.H., Kegel, K.B., Yoder, J., Comer-Tierney, L.A., Esteves, M., Chase, K. et al. (2009) Mutant huntingtin impairs vesicle formation from recycling endosomes by interfering with Rab11 activity. Mol. Cell Biol., 29, 6106-6116.
35. Chung, C.Y., Koprich, J.B., Hallett, P.J. and Isacson, O. (2009) Functional enhancement and protection of dopaminergic terminals by RAB3B overexpression. Proc. Natl. Acad. Sci. USA, 106, 22474-22479.
36. Li, G. (2011) Rab GTPases, membrane trafficking and diseases. Curr. Drug Targets, 12, 1188-1193.
37. Li, X., Sapp, E., Chase, K., Comer-Tierney, L.A., Masso, N., Alexander, J., Reeves, P., Kegel, K.B., Valencia, A., Esteves, M. et al. (2009) Disruption of Rab11 activity in a knock-in mouse model of Huntington's disease. Neurobiol. Dis., 36, 374-383.
38. Dalbem, A., Silveira, C.V., Pedroso, M.F., Breda, R.V., Werne Baes, C.V., Bartmann, A.P. and da Costa, J.C. (2005) Altered distribution of striatal activity-dependent synaptic plasticity in the 3-nitropropionic acid model of Huntington's disease. Brain Res., 1047, 148-158.
39. Gibson, H.E., Reim, K., Brose, N., Morton, A.J. and Jones, S. (2005) A similar impairment in CA3 mossy fibre LTP in the R6/2 mouse model of Huntington's disease and in the complexin II knockout mouse. Eur. J. Neurosci., 22, 1701-1712.
40. Kung, V.W., Hassam, R., Morton, A.J. and Jones, S. (2007) Dopamine-dependent long term potentiation in the dorsal striatum is reduced in the R6/2 mouse model of Huntington's disease. Neuroscience, 146, 1571-1580.
41. Milnerwood, A.J. and Raymond, L.A. (2007) Corticostriatal synaptic function in mouse models of Huntington's disease: early effects of huntingtin repeat length and protein load. J. Physiol., 585, 817-831.
42. Usdin, M.T., Shelbourne, P.F., Myers, R.M. and Madison, D.V. (1999) Impaired synaptic plasticity in mice carrying the Huntington's disease mutation. Hum. Mol. Genet., 8, 839-846.
43. Schilling, G., Becher, M.W., Sharp, A.H., Jinnah, H.A., Duan, K., Kotzuk, J.A., Slunt, H.H., Ratovitski, T., Cooper, J.K., Jenkins, N.A. et al. (1999) Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum. Mol. Genet., 8, 397-407.
44. Bayram-Weston, Z., Jones, L., Dunnett, S.B. and Brooks, S.P. (2012) Light and electron microscopic characterization of the evolution of cellular pathology in the R6/1 Huntington's disease transgenic mice. Brain. Res. Bull., 88, 104-112.
45. Bayram-Weston, Z., Jones, L., Dunnett, S.B. and Brooks, S.P. (2012) Light and electron microscopic characterization of the evolution of cellular pathology in YAC128 Huntington's disease transgenic mice. Brain. Res. Bull., 88, 137-147.
46. Gabery, S., Sajjad, M.U., Hult, S., Soylu, R., Kirik, D. and Petersen, A. (2012) Characterization of a rat model of Huntington's disease based on targeted expression of mutant huntingtin in the forebrain using adeno-associated viral vectors. Eur. J. Neurosci., 36, 2789-2800.
47. Tabrizi, S.J., Scahill, R.I., Owen, G., Durr, A., Leavitt, B.R., Roos, R.A., Borowsky, B., Landwehrmeyer, B., Frost, C., Johnson, H. et al. (2013) Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol., 12, 637-649.
48. Slow, E.J., van Raamsdonk, J., Rogers, D., Coleman, S.H., Graham, R.K., Deng, Y., Oh, R., Bissada, N., Hossain, S.M., Yang, Y.Z. et al. (2003) Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum. Mol. Genet., 12, 1555-1567.
49. Lastres-Becker, I., Hansen, H.H., Berrendero, F., De Miguel, R., Perez-Rosado, A., Manzanares, J., Ramos, J.A. and Fernandez-Ruiz, J. (2002) Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease. Synapse, 44, 23-35.
50. Reiner, A., Dragatsis, I. and Dietrich, P. (2011) Genetics and neuropathology of Huntington's disease. Int. Rev. Neurobiol., 98, 325-372.
51. Sotrel, A., Paskevich, P.A., Kiely, D.K., Bird, E.D., Williams, R.S. and Myers, R.H. (1991) Morphometric analysis of the prefrontal cortex in Huntington's disease. Neurology, 41, 1117-1123.
52. Al-Abdulla, N.A. and Martin, L.J. (1998) Apoptosis of retrogradely degenerating neurons occurs in association with the accumulation of perikaryal mitochondria and oxidativedamageto the nucleus.Am.J. Pathol., 153, 447-456.
53. Deng, Y.P., Wong, T., Bricker-Anthony, C., Deng, B. and Reiner, A. (2013) Loss of corticostriatal and thalamostriatal synaptic terminals precedes striatal projection neuron pathology in heterozygous Q140 Huntington's disease mice. Neurobiol. Dis., 60, 89-107.
54. Cha, J.H., Kosinski, C.M., Kerner, J.A., Alsdorf, S.A., Mangiarini, L., Davies, S.W., Penney, J.B., Bates, G.P. and Young, A.B. (1998) Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene. Proc. Natl. Acad. Sci. USA, 95, 6480-6485.
55. Carter, R.J., Lione, L.A., Humby, T., Mangiarini, L., Mahal, A., Bates, G.P., Dunnett, S.B. and Morton, A.J. (1999) Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J. Neurosci., 19, 3248-3257.
56. Nicniocaill, B., Haraldsson, B., Hansson, O., O'Connor, W.T. and Brundin, P. (2001) Altered striatal amino acid neurotransmitter release monitored using microdialysis in R6/1 Huntington transgenic mice. Eur. J. Neurosci., 13, 206-210.
57. Loh, D.H., Kudo, T., Truong, D., Wu, Y. and Colwell, C.S. (2013) The Q175 mouse model of Huntington's disease shows gene dosage- and age-related decline in circadian rhythms of activity and sleep. PLoS One, 8, e69993.
58. Morton, A.J. (2013) Circadian and sleep disorder in Huntington's disease. Exp. Neurol., 243, 34-44.
59. Andre, V.M., Fisher, Y.E. and Levine, M.S. (2011) Altered balance of activity in the striatal direct and indirect pathways in mouse models of Huntington's disease. Front. Syst. Neurosci., 5, 46.
60. Callahan, J.W. and Abercrombie, E.D. (2011) In vivo dopamine efflux is decreased in striatum of both fragment (R6/2) and full-Length (YAC128) transgenic mouse models of Huntington's disease. Front. Syst. Neurosci., 5, 61.
61. Gorlich, D. and Mattaj, I.W. (1996) Nucleocytoplasmic transport. Science, 271, 1513-1518.
62. Rubinsztein, D.C. and Carmichael, J. (2003) Huntington's disease: molecular basis of neurodegeneration. Expert. Rev. Mol. Med., 5, 1-21.
63. Waldron-Roby, E., Ratovitski, T., Wang, X., Jiang, M., Watkin, E., Arbez, N., Graham, R.K., Hayden, M.R., Hou, Z., Mori, S. et al. (2012) Transgenic mouse model expressing the caspase 6 fragment of mutant huntingtin. J. Neurosci., 32, 183-193.
64. Thompson, L.M., Aiken, C.T., Kaltenbach, L.S., Agrawal, N., Illes, K., Khoshnan, A., Martinez-Vincente, M., Arrasate, M., O'Rourke, J.G., Khashwji, H. et al. (2009) IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome. J. Cell. Biol., 187, 1083-1099.
65. Ikenaka, K., Kawai, K., Katsuno, M., Huang, Z., Jiang, Y.M., Iguchi, Y., Kobayashi, K., Kimata, T., Waza, M., Tanaka, F. et al. (2013) dnc-1/ dynactin 1 knockdown disrupts transport of autophagosomes and induces motor neuron degeneration. PLoS One, 8, e54511.
66. Pilling, A.D., Horiuchi, D., Lively,C.M. and Saxton,W.M.(2006) Kinesin-1 and Dynein are the primary motors for fast transport of mitochondria in Drosophila motor axons. Mol. Biol. Cell, 17, 2057-2068.
67. Eschbach, J. and Dupuis, L. (2011) Cytoplasmic dynein in neurodegeneration. Pharmacol. Ther., 130, 348-363.
68. Caviston, J.P., Ross, J.L., Antony, S.M., Tokito, M. and Holzbaur, E.L. (2007) Huntingtin facilitates dynein/dynactin-mediated vesicle transport. Proc. Natl. Acad. Sci. USA, 104, 10045-10050.
69. Altar, C.A., Cai, N., Bliven, T., Juhasz, M., Conner, J.M., Acheson, A.L., Lindsay, R.M. and Wiegand, S.J. (1997) Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature, 389, 856-860.
70. Giampa, C., Montagna, E., Dato, C., Melone, M.A., Bernardi, G. and Fusco, F.R. (2013) Systemic delivery of recombinant brain derived neurotrophic factor (BDNF) in the R6/2 mouse model of Huntington's disease. PLoS One, 8, e64037.
71. Samadi, P., Boutet, A., Rymar, V.V., Rawal, K., Maheux, J., Kvann, J.C., Tomaszewski, M., Beaubien, F., Cloutier, J.F., Levesque, D. et al. (2013) Relationship between BDNF expression in major striatal afferents, striatum morphology and motor behavior in the R6/2 mouse model of Huntington's disease. Genes Brain Behav., 12, 108-124.
72. Gokce, O., Runne, H., Kuhn, A. and Luthi-Carter, R. (2009) Short-term striatal gene expression responses to brain-derived neurotrophic factor are dependent on MEK and ERK activation. PLoS One, 4, e5292.
73. Lu, B., Nagappan, G., Guan, X., Nathan, P.J. and Wren, P. (2013) BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases. Nat. Rev. Neurosci., 14, 401-416.
74. Murmu, R.P., Li, W., Holtmaat, A. and Li, J.Y. (2013) Dendritic spine instability leads to progressive neocortical spine loss in a mouse model of Huntington's disease. J. Neurosci., 33, 12997-13009.
75. Nithianantharajah, J. and Hannan, A.J. (2012) Dysregulation of synaptic proteins, dendritic spine abnormalities and pathological plasticity of synapses as experience-dependent mediators of cognitive and psychiatric symptoms in Huntington's disease. Neuroscience, 251, 66-74.
76. DiProspero, N.A., Chen, E.Y., Charles, V., Plomann, M., Kordower, J.H. and Tagle, D.A. (2004) Early changes in Huntington's disease patient brains involve alterations in cytoskeletal and synaptic elements. J. Neurocytol., 33, 517-533.
77. Wojtowicz, A.M., Dvorzhak, A., Semtner, M. and Grantyn, R. (2013) Reduced tonic inhibition in striatal output neurons from Huntington mice due to loss of astrocytic GABA release through GAT-3. Front. Neural Circuits, 7, 188.
78. Heikkinen, T., Lehtimaki, K., Vartiainen, N., Puolivali, J., Hendricks, S.J., Glaser, J.R., Bradaia, A., Wadel, K., Touller, C., Kontkanen,O. et al. (2012) Characterization of neurophysiological and behavioral changes, MRI brain volumetry and 1H MRS in zQ175 knock-in mouse model of Huntington's disease. PLoS One, 7, e50717.
79. Castillo, P.E., Janz, R., Sudhof, T.C., Tzounopoulos, T., Malenka, R.C. and Nicoll, R.A. (1997) Rab3A is essential for mossy fibre long-term potentiation in the hippocampus. Nature, 388, 590-593.
80. Smith, R., Klein, P., Koc-Schmitz, Y., Waldvogel, H.J., Faull, R.L., Brundin, P., Plomann, M.and Li, J.Y. (2007) Loss of SNAP-25and rabphilin 3a in sensory-motor cortex in Huntington's disease. J. Neurochem., 103, 115-123.
81. Stowers, R.S. and Isacoff, E.Y. (2007) Drosophila huntingtin-interacting protein 14 is a presynaptic protein required for photoreceptor synaptic transmission and expression of the palmitoylated proteins synaptosome-associated protein 25 and cysteine string protein. J. Neurosci., 27, 12874-12883.
82. Cattaneo, E., Rigamonti, D., Goffredo, D., Zuccato, C., Squitieri, F. and Sipione, S. (2001) Loss of normal huntingtin function: new developments in Huntington's disease research. Trends Neurosci., 24, 182-188.
83. Hu, D., Cao, Y., He, R., Han, N., Liu, Z., Miao, L. and Yin, J. (2012) Schizandrin, an antioxidant lignan from Schisandra chinensis, ameliorates Abeta1-42-induced memory impairment in mice. Oxid. Med. Cell Longev., 2012, 721721.
84. Deacon, R.M. (2006) Assessing nest building in mice. Nat. Protoc., 1, 1117-1119.